Lonafarnib

CHEMBL298734 Phase 4 Approuvé Small molecule

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

638.8 g/mol

LogP

4.8

Phase

4

A farnesyltransferase inhibitor used to treat Hutchinson-Gilford progeria syndrome, a rare premature aging condition, and studied in hepatitis D infection. It blocks the processing of a defective protein that causes rapid cellular aging in progeria patients.

Masse moléculaire

638,8000 g/mol

LogP

4,80

TPSA

79,50 Å²

Règle des 5 de Lipinski

Conforme

Aires thérapeutiques

Ovarian Cancer Pancreatic Cancer Bladder Cancer Thyroid Cancer Non-Small Cell Lung Cancer Non-Alcoholic Fatty Liver Disease Lymphoma Breast Cancer Prostate Cancer Colorectal Cancer Leukemia

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Structure 2D

SVG PNG

Cite this structure

Embed this structure

SMILES

NC(=O)N1CCC(CC(=O)N2CCC([C@H]3c4ncc(Br)cc4CCc4cc(Cl)cc(Br)c43)CC2)CC1

InChI

InChI=1S/C27H31Br2ClN4O2/c28-20-12-19-2-1-18-13-21(30)14-22(29)24(18)25(26(19)32-15-20)17-5-9-33(10-6-17)23(35)11-16-3-7-34(8-4-16)27(31)36/h12-17,25H,1-11H2,(H2,31,36)/t25-/m1/s1

Molecular Formula

C27H31Br2ClN4O2

HBD / HBA

1 / 3

Liaisons Rotatives

3

Atomes Lourds

36

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Foire aux questions

A farnesyltransferase inhibitor used to treat Hutchinson-Gilford progeria syndrome, a rare premature aging condition, and studied in hepatitis D infection. It blocks the processing of a defective protein that causes rapid cellular aging in progeria patients.

Yes, Lonafarnib is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL298734. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 148195. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

PillFYI

Vous cherchez des informations accessibles aux patients ?

Lonafarnib sur PillFYI

Structure

Données Clés

Formule: C27H31Br2ClN4O2
Synonymes: 1

Liens externes

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

Avertissement médical

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.